22/120
0.9 / 5 stars
All 120 Win/Lose results shown below
TVTX Roast Me summary
Travere Therapeutics, Inc. (TVTX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseTVTX / S&P TVTX unavailable / 15.20% |
WinTVTX / S&P 77.12% / 15.00% |
LoseTVTX / S&P TVTX unavailable / 50.40% |
| 2026-Q11/3 |
LoseTVTX / S&P TVTX unavailable / -4.33% |
WinTVTX / S&P 96.03% / 11.30% |
LoseTVTX / S&P TVTX unavailable / 27.70% |
| 2025-Q41/3 |
LoseTVTX / S&P TVTX unavailable / 2.65% |
WinTVTX / S&P 110.45% / 9.00% |
LoseTVTX / S&P TVTX unavailable / 13.40% |
| 2025-Q31/3 |
LoseTVTX / S&P TVTX unavailable / 8.12% |
WinTVTX / S&P 114.22% / 4.61% |
LoseTVTX / S&P TVTX unavailable / 13.45% |
| 2025-Q21/3 |
LoseTVTX / S&P TVTX unavailable / 10.94% |
WinTVTX / S&P 87.94% / 4.83% |
LoseTVTX / S&P TVTX unavailable / 10.63% |
| 2025-Q11/3 |
LoseTVTX / S&P TVTX unavailable / -4.27% |
WinTVTX / S&P 75.65% / 4.98% |
LoseTVTX / S&P TVTX unavailable / 10.57% |
| 2024-Q41/3 |
LoseTVTX / S&P TVTX unavailable / 2.41% |
WinTVTX / S&P 60.55% / 5.25% |
LoseTVTX / S&P TVTX unavailable / 6.15% |
| 2024-Q31/3 |
LoseTVTX / S&P TVTX unavailable / 5.89% |
WinTVTX / S&P 57.08% / 5.89% |
LoseTVTX / S&P TVTX unavailable / 6.11% |
| 2024-Q21/3 |
LoseTVTX / S&P TVTX unavailable / 4.28% |
WinTVTX / S&P 47.42% / 5.38% |
LoseTVTX / S&P TVTX unavailable / 5.12% |
| 2024-Q11/3 |
LoseTVTX / S&P TVTX unavailable / 10.56% |
WinTVTX / S&P 9.30% / 5.71% |
LoseTVTX / S&P TVTX unavailable / 5.59% |
| 2023-Q41/3 |
LoseTVTX / S&P TVTX unavailable / 11.69% |
WinTVTX / S&P 32.69% / 6.81% |
LoseTVTX / S&P TVTX unavailable / 7.78% |
| 2023-Q31/3 |
LoseTVTX / S&P TVTX unavailable / -3.27% |
WinTVTX / S&P 40.29% / 7.52% |
LoseTVTX / S&P TVTX unavailable / -5.03% |
| 2023-Q20/3 |
LoseTVTX / S&P TVTX unavailable / 8.74% |
LoseTVTX / S&P -9.03% / 9.50% |
LoseTVTX / S&P TVTX unavailable / -8.57% |
| 2023-Q10/3 |
LoseTVTX / S&P TVTX unavailable / 7.50% |
LoseTVTX / S&P 7.19% / 10.77% |
LoseTVTX / S&P TVTX unavailable / -15.69% |
| 2022-Q40/3 |
LoseTVTX / S&P TVTX unavailable / 7.56% |
LoseTVTX / S&P -16.97% / 11.88% |
LoseTVTX / S&P TVTX unavailable / -17.99% |
| 2022-Q30/3 |
LoseTVTX / S&P TVTX unavailable / -4.88% |
LoseTVTX / S&P -58.27% / 13.47% |
LoseTVTX / S&P TVTX unavailable / -1.41% |
| 2022-Q20/3 |
LoseTVTX / S&P TVTX unavailable / -16.10% |
LoseTVTX / S&P -35.11% / 13.71% |
LoseTVTX / S&P TVTX unavailable / 11.04% |
| 2022-Q10/3 |
LoseTVTX / S&P TVTX unavailable / -4.60% |
LoseTVTX / S&P -32.86% / 15.97% |
LoseTVTX / S&P TVTX unavailable / 42.23% |
| 2021-Q40/3 |
LoseTVTX / S&P TVTX unavailable / 11.03% |
LoseTVTX / S&P -33.52% / 15.00% |
LoseTVTX / S&P TVTX unavailable / 96.40% |
| 2021-Q31/3 |
LoseTVTX / S&P TVTX unavailable / 0.58% |
WinTVTX / S&P 14.02% / 10.77% |
LoseTVTX / S&P TVTX unavailable / 69.42% |
| 2021-Q21/3 |
LoseTVTX / S&P TVTX unavailable / 8.55% |
WinTVTX / S&P 9.02% / 6.58% |
LoseTVTX / S&P TVTX unavailable / 51.81% |
| 2021-Q11/3 |
LoseTVTX / S&P TVTX unavailable / 6.17% |
WinTVTX / S&P 7.86% / -1.06% |
LoseTVTX / S&P TVTX unavailable / 7.39% |
| 2020-Q41/3 |
LoseTVTX / S&P TVTX unavailable / 12.15% |
WinTVTX / S&P 13.11% / -3.72% |
LoseTVTX / S&P TVTX unavailable / -33.42% |
| 2020-Q31/3 |
LoseTVTX / S&P TVTX unavailable / 8.93% |
WinTVTX / S&P 12.53% / -2.04% |
LoseTVTX / S&P TVTX unavailable / -27.10% |
| 2020-Q21/3 |
LoseTVTX / S&P TVTX unavailable / 20.54% |
WinTVTX / S&P 10.97% / -0.46% |
LoseTVTX / S&P TVTX unavailable / -27.11% |
| 2020-Q11/3 |
LoseTVTX / S&P TVTX unavailable / -19.60% |
WinTVTX / S&P 10.98% / 3.47% |
LoseTVTX / S&P TVTX unavailable / -14.75% |
| 2019-Q41/3 |
LoseTVTX / S&P TVTX unavailable / 9.07% |
WinTVTX / S&P 6.75% / 5.36% |
LoseTVTX / S&P TVTX unavailable / 2.99% |
| 2019-Q31/3 |
LoseTVTX / S&P TVTX unavailable / 1.70% |
WinTVTX / S&P 6.01% / 5.02% |
LoseTVTX / S&P TVTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseTVTX / S&P TVTX unavailable / 4.30% |
LoseTVTX / S&P 3.99% / 6.64% |
LoseTVTX / S&P TVTX unavailable / 8.65% |
| 2019-Q10/3 |
LoseTVTX / S&P TVTX unavailable / 13.65% |
LoseTVTX / S&P 3.53% / 8.12% |
LoseTVTX / S&P TVTX unavailable / 14.29% |
| 2018-Q40/3 |
LoseTVTX / S&P TVTX unavailable / -13.52% |
LoseTVTX / S&P 6.01% / 9.05% |
LoseTVTX / S&P TVTX unavailable / 18.23% |
| 2018-Q30/3 |
LoseTVTX / S&P TVTX unavailable / 7.71% |
LoseTVTX / S&P TVTX unavailable / 10.21% |
LoseTVTX / S&P TVTX unavailable / 19.06% |
| 2018-Q20/3 |
LoseTVTX / S&P TVTX unavailable / 3.43% |
LoseTVTX / S&P TVTX unavailable / 9.03% |
LoseTVTX / S&P TVTX unavailable / 14.46% |
| 2018-Q10/3 |
LoseTVTX / S&P TVTX unavailable / -0.76% |
LoseTVTX / S&P TVTX unavailable / 7.68% |
LoseTVTX / S&P TVTX unavailable / 12.46% |
| 2017-Q41/3 |
LoseTVTX / S&P TVTX unavailable / 6.64% |
WinTVTX / S&P 15.98% / 7.03% |
LoseTVTX / S&P TVTX unavailable / 13.82% |
| 2017-Q30/3 |
LoseTVTX / S&P TVTX unavailable / 4.48% |
LoseTVTX / S&P TVTX unavailable / 5.68% |
LoseTVTX / S&P TVTX unavailable / 17.57% |
| 2017-Q20/3 |
LoseTVTX / S&P TVTX unavailable / 3.09% |
LoseTVTX / S&P TVTX unavailable / 4.83% |
LoseTVTX / S&P -256.67% / 17.74% |
| 2017-Q10/3 |
LoseTVTX / S&P TVTX unavailable / 6.07% |
LoseTVTX / S&P TVTX unavailable / 3.67% |
LoseTVTX / S&P -327.38% / 13.32% |
| 2016-Q40/3 |
LoseTVTX / S&P TVTX unavailable / 3.82% |
LoseTVTX / S&P TVTX unavailable / 2.09% |
LoseTVTX / S&P -140.69% / 7.05% |
| 2016-Q30/3 |
LoseTVTX / S&P TVTX unavailable / 3.85% |
LoseTVTX / S&P TVTX unavailable / 0.20% |
LoseTVTX / S&P -232.77% / -3.15% |
Dividend-reinvested, split-adjusted total return
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |